{"hands_on_practices": [{"introduction": "Clinical diagnosis is a process of updating belief in the face of new evidence. This fundamental exercise demonstrates how to move from clinical suspicion to a quantitative post-test probability using the principles of conditional probability. By applying these concepts to a common diagnostic test for Pelvic Inflammatory Disease (PID), you will practice a core skill of evidence-based medicine: interpreting the true meaning of a positive test result within a specific clinical context [@problem_id:4484791].", "problem": "A reproductive-age patient presents to an emergency department with pelvic pain and cervical motion tenderness. Clinician synthesis of history, examination, and local epidemiology yields a pretest probability for Pelvic Inflammatory Disease (PID) of $0.35$. In this symptomatic cohort, positivity on a Nucleic Acid Amplification Test (NAAT) for Neisseria gonorrhoeae or Chlamydia trachomatis is used as a diagnostic indicator for PID relative to a laparoscopic reference standard, with sensitivity $0.62$ and specificity $0.92$ for PID. Assume that these operating characteristics are applicable to this patient’s population and that the NAAT returns positive.\n\nUsing only the core definitions of sensitivity, specificity, and conditional probability, and without invoking any unprovided shortcut formulas, derive from first principles the post-test probability of PID given a positive NAAT in this patient. Express the final result as a decimal probability and round your answer to four significant figures.", "solution": "The problem will be validated by first extracting the given information and then assessing its scientific grounding, consistency, and structure.\n\n### Step 1: Extract Givens\n- Pretest probability for Pelvic Inflammatory Disease (PID): $P_{\\text{pretest}}(\\text{PID}) = 0.35$\n- Diagnostic indicator: Positivity on a Nucleic Acid Amplification Test (NAAT) for *Neisseria gonorrhoeae* or *Chlamydia trachomatis*.\n- Reference standard for PID diagnosis: Laparoscopy\n- Sensitivity of NAAT for PID: $S_n = 0.62$\n- Specificity of NAAT for PID: $S_p = 0.92$\n- Patient's test result: The NAAT returns positive.\n- Objective: Derive the post-test probability of PID given a positive NAAT from first principles.\n- Final format: Decimal probability rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the specified criteria:\n- **Scientifically Grounded and Objective (Critical)**: The problem is a standard application of conditional probability and Bayesian inference to the domain of medical diagnostics. The concepts of pretest probability (prevalence in the relevant cohort), sensitivity, and specificity are fundamental to evidence-based medicine. The values provided are clinically plausible for the given scenario. The problem is stated in objective, formal language.\n- **Well-Posed**: All necessary information is provided. The pretest probability, sensitivity, and specificity are sufficient to calculate the post-test probability (positive predictive value) using the principles of probability theory. A unique and meaningful solution exists.\n- **Completeness and Consistency**: The problem is self-contained and free of contradictions. The data are numerically and conceptually consistent.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete, reasoned solution will be provided.\n\n### Solution Derivation\nLet $D$ be the event that the patient has Pelvic Inflammatory Disease (PID).\nLet $D^c$ be the event that the patient does not have PID.\nLet $T$ be the event that the Nucleic Acid Amplification Test (NAAT) is positive.\nLet $T^c$ be the event that the NAAT is negative.\n\nThe given information can be formally expressed in the language of probability theory:\n1.  The pretest probability of PID is given as $P(D) = 0.35$.\n2.  The probability of not having PID is the complement, so $P(D^c) = 1 - P(D) = 1 - 0.35 = 0.65$.\n3.  The sensitivity of the test is the probability of a positive test result given that the disease is present: $P(T|D) = 0.62$.\n4.  The specificity of the test is the probability of a negative test result given that the disease is absent: $P(T^c|D^c) = 0.92$.\n\nFrom the definition of specificity, we can determine the probability of a positive test result given that the disease is absent (the false positive rate). This is the complement of specificity:\n$$P(T|D^c) = 1 - P(T^c|D^c) = 1 - 0.92 = 0.08$$\n\nThe objective is to find the post-test probability of PID given a positive NAAT. This is the conditional probability $P(D|T)$.\n\nWe begin from the fundamental definition of conditional probability:\n$$P(D|T) = \\frac{P(D \\cap T)}{P(T)}$$\nwhere $P(D \\cap T)$ is the joint probability of having the disease and testing positive, and $P(T)$ is the total probability of testing positive.\n\nFirst, we express the numerator, $P(D \\cap T)$, using the definition of conditional probability, which can be rearranged as $P(A \\cap B) = P(A|B)P(B)$. Thus:\n$$P(D \\cap T) = P(T|D) P(D)$$\nThis term represents the true positives. Substituting the given values:\n$$P(D \\cap T) = 0.62 \\times 0.35 = 0.217$$\n\nNext, we express the denominator, $P(T)$, using the law of total probability. A positive test result can occur in two mutually exclusive ways:\n1.  The patient has the disease and tests positive ($D \\cap T$).\n2.  The patient does not have the disease and tests positive ($D^c \\cap T$).\n\nThe total probability $P(T)$ is the sum of the probabilities of these two events:\n$$P(T) = P(D \\cap T) + P(D^c \\cap T)$$\nWe have already calculated the first term. The second term, $P(D^c \\cap T)$, which represents the false positives, can be similarly expanded:\n$$P(D^c \\cap T) = P(T|D^c) P(D^c)$$\nSubstituting the known values:\n$$P(D^c \\cap T) = 0.08 \\times 0.65 = 0.052$$\nNow, we can calculate the total probability of a positive test:\n$$P(T) = 0.217 + 0.052 = 0.269$$\n\nFinally, we substitute the calculated values for the numerator and the denominator back into the expression for $P(D|T)$:\n$$P(D|T) = \\frac{P(D \\cap T)}{P(T)} = \\frac{0.217}{0.269}$$\nPerforming the division:\n$$P(D|T) \\approx 0.8066914498...$$\nThe problem requires the final result to be rounded to four significant figures.\n$$P(D|T) \\approx 0.8067$$\nThis represents the post-test probability of the patient having PID given her positive test result.", "answer": "$$\\boxed{0.8067}$$", "id": "4484791"}, {"introduction": "Once PID is suspected and imaging reveals a complex adnexal mass, the crucial next step is to solidify the diagnosis. This practice challenges you to integrate a rich clinical dataset—spanning history, laboratory markers, and multi-modality imaging—to distinguish a tubo-ovarian abscess (TOA) from its key mimics. You will reason from the first principles of pathophysiology and the physics of advanced imaging techniques like Diffusion-Weighted MRI to arrive at a definitive conclusion, honing the expert-level synthesis required in complex cases [@problem_id:4484828].", "problem": "A $27$-year-old nulliparous woman presents with $48$ hours of lower abdominal and pelvic pain, fever of $39.2^\\circ\\mathrm{C}$, and purulent vaginal discharge. On bimanual examination, there is marked cervical motion tenderness. Laboratory studies show White Blood Cells (WBC) $16,500/\\mu\\text{L}$, C-Reactive Protein (CRP) $120 \\text{ mg/L}$, and Erythrocyte Sedimentation Rate (ESR) $55 \\text{ mm/hr}$. Urine human chorionic gonadotropin (hCG) is negative. Transvaginal Ultrasonography (TVUS) reveals a right adnexal complex mass measuring $6.8 \\times 5.6 \\text{ cm}$ with thick septations up to $4 \\text{ mm}$, internal low-level echoes with fluid-debris levels, and peripheral color Doppler hyperemia with no discernible internal vascular flow. There is moderate complex pelvic free fluid, and the adjacent pelvic fat appears echogenic. Computed Tomography (CT) of the pelvis demonstrates rim enhancement of the mass, stranding of adjacent fat, and punctate gas locules within the lesion. Magnetic Resonance Imaging (MRI) with Diffusion-Weighted Imaging (DWI) shows marked diffusion restriction with an Apparent Diffusion Coefficient (ADC) of $0.60\\times 10^{-3}\\ \\mathrm{mm}^2/\\mathrm{s}$ within the cavity; there is no classic T$2$ “shading” pattern.\n\nUsing fundamental definitions of infectious pelvic pathology versus hemorrhagic ovarian cysts, and the physical basis of diffusion MRI, reason from first principles to classify the adnexal lesion as either Tubo-Ovarian Abscess (TOA) or hemorrhagic ovarian cyst. Select the single best classification among the options.\n\nA. Tubo-ovarian abscess requiring broad-spectrum intravenous antibiotics, with image-guided drainage if there is lack of clinical improvement\n\nB. Hemorrhagic ovarian cyst managed conservatively with analgesia and repeat imaging in $6$–$8$ weeks\n\nC. Ovarian torsion requiring urgent laparoscopic detorsion\n\nD. Ruptured ectopic pregnancy requiring emergent surgical management", "solution": "The problem statement is subjected to validation before proceeding to a solution.\n\n### Step 1: Extract Givens\n- **Patient Profile:** A $27$-year-old nulliparous woman.\n- **Clinical Presentation:** $48$ hours of lower abdominal and pelvic pain, fever of $39.2^\\circ\\mathrm{C}$, and purulent vaginal discharge.\n- **Physical Examination:** Marked cervical motion tenderness.\n- **Laboratory Data:**\n  - White Blood Cells (WBC): $16{,}500/\\mu\\mathrm{L}$ with left shift.\n  - C-Reactive Protein (CRP): $120\\ \\mathrm{mg/L}$.\n  - Erythrocyte Sedimentation Rate (ESR): $55\\ \\mathrm{mm/hr}$.\n  - Urine human chorionic gonadotropin (hCG): negative.\n- **Transvaginal Ultrasonography (TVUS) Data:**\n  - Right adnexal complex mass measuring $6.8\\times 5.6\\ \\mathrm{cm}$.\n  - Thick septations up to $4\\ \\mathrm{mm}$.\n  - Internal low-level echoes with fluid-debris levels.\n  - Peripheral color Doppler hyperemia.\n  - No discernible internal vascular flow.\n  - Moderate complex pelvic free fluid.\n  - Adjacent pelvic fat appears echogenic.\n- **Computed Tomography (CT) Data:**\n  - Rim enhancement of the mass.\n  - Stranding of adjacent fat.\n  - Punctate gas locules within the lesion.\n- **Magnetic Resonance Imaging (MRI) Data:**\n  - Diffusion-Weighted Imaging (DWI) shows marked diffusion restriction within the cavity.\n  - Apparent Diffusion Coefficient (ADC) of $0.60\\times 10^{-3}\\ \\mathrm{mm}^2/\\mathrm{s}$.\n  - No classic T$2$ “shading” pattern.\n- **Task:** Classify the adnexal lesion as either Tubo-Ovarian Abscess (TOA) or hemorrhagic ovarian cyst based on first principles.\n\n### Step 2: Validate Using Extracted Givens\nThe problem provides a detailed clinical vignette with history, physical exam, laboratory, and multi-modality imaging findings.\n- **Scientifically Grounded:** The described clinical scenario, laboratory values, and imaging characteristics are classic and well-documented representations of pelvic inflammatory disease complicated by a tubo-ovarian abscess. The use of DWI/ADC physics for tissue characterization is a standard, scientifically-validated technique in radiology. All data are consistent with established medical science.\n- **Well-Posed:** The problem is well-posed. It provides sufficient, consistent data to allow for a differential diagnosis and a definitive conclusion through logical deduction. The question is specific and answerable.\n- **Objective:** The data are presented using objective, quantitative (e.g., lab values, measurements) and standard qualitative medical descriptors (e.g., \"purulent,\" \"rim enhancement\"). There is no subjective or ambiguous language.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. It is a scientifically sound, well-posed, and objective clinical problem that can be solved by applying fundamental principles of pathophysiology and medical imaging.\n\n### Derivation\nThe task is to differentiate between a Tubo-Ovarian Abscess (TOA) and a hemorrhagic ovarian cyst. We will analyze the evidence from first principles.\n\n1.  **Clinical and Laboratory Evidence of Infection:**\n    The patient presents with a triad of acute lower abdominal pain, high fever ($39.2^\\circ\\mathrm{C}$), and purulent vaginal discharge. Physical examination reveals marked cervical motion tenderness. This clinical constellation is the hallmark of Pelvic Inflammatory Disease (PID), an infection of the upper female genital tract. Laboratory findings corroborate a significant systemic inflammatory response to infection:\n    - Marked leukocytosis ($16{,}500/\\mu\\mathrm{L}$) with a left shift indicates an acute bacterial infection.\n    - Highly elevated inflammatory markers (CRP $120\\ \\mathrm{mg/L}$, ESR $55\\ \\mathrm{mm/hr}$) further support a severe inflammatory process.\n    A hemorrhagic cyst typically causes pain due to stretching of the ovarian capsule or rupture with hemoperitoneum, but it does not intrinsically cause high fever, purulent discharge, or the profound systemic inflammatory response seen here.\n\n2.  **Exclusion of Pregnancy-Related Pathology:**\n    The negative urine hCG result is a critical datum. It reliably excludes pathologies related to pregnancy, such as a ruptured ectopic pregnancy or a hemorrhagic corpus luteum cyst of pregnancy.\n\n3.  **Multi-Modality Imaging Analysis:**\n    The imaging findings across three modalities (US, CT, MRI) provide a cohesive and definitive picture.\n\n    - **Ultrasound:** A TOA is classically a complex, multiloculated adnexal mass, often with thick walls and septa ($3\\ \\mathrm{mm}$), filled with complex fluid containing low-level echoes or fluid-debris levels. The findings of a $6.8\\times 5.6\\ \\mathrm{cm}$ mass with thick ($4\\ \\mathrm{mm}$) septations and fluid-debris levels are characteristic. The peripheral hyperemia on Doppler represents the intense inflammatory vascularity in the abscess wall. The absence of internal flow is expected, as the abscess cavity contains avascular pus. The surrounding findings of echogenic fat and complex free fluid indicate associated pelvic peritonitis, a common extension of the infectious process. While a hemorrhagic cyst can be complex, it more typically shows a reticular pattern of fibrin strands, has thinner walls, and does not usually elicit such a profound surrounding inflammatory reaction.\n\n    - **CT:** The CT findings are highly specific for an abscess. Rim enhancement of the wall is the classic sign of an encapsulated fluid collection with a hypervascular inflammatory capsule. Fat stranding is the CT correlate of the inflammatory changes in the pelvic fat seen on ultrasound. The most specific finding is the presence of **punctate gas locules**. Gas within a non-gastrointestinal collection is virtually pathognomonic for an infection with gas-forming organisms (typically anaerobes). It is impossible for a sterile hemorrhagic cyst to contain gas.\n\n    - **MRI and Diffusion Physics:** The MRI findings provide the final, conclusive piece of evidence based on physical principles.\n        - **Diffusion-Weighted Imaging (DWI)** measures the random, thermally-driven motion (Brownian motion) of water molecules. The signal intensity on DWI is inversely related to the degree of water motion.\n        - **Apparent Diffusion Coefficient (ADC)** provides a quantitative map of the magnitude of diffusion.\n        - The substance within an abscess is pus, a highly viscous fluid composed of a dense matrix of living and dead neutrophils, bacteria, necrotic tissue, and proteinaceous exudate. This dense, cellular environment severely restricts the random motion of water molecules.\n        - Consequently, an abscess cavity demonstrates markedly restricted diffusion, which manifests as high signal on DWI and a very low ADC value. The measured ADC of $0.60\\times 10^{-3}\\ \\mathrm{mm}^2/\\mathrm{s}$ is extremely low and is a signature finding for pus. In contrast, the fluid in a hemorrhagic cyst consists of blood products and serum. While diffusion may be slightly restricted compared to simple fluid (which has an ADC near $3.0\\times 10^{-3}\\ \\mathrm{mm}^2/\\mathrm{s}$), it is significantly less restricted than in pus; the ADC for subacute hemorrhage is typically in the range of $1.0-1.6\\times 10^{-3}\\ \\mathrm{mm}^2/\\mathrm{s}$. The measured value of $0.60\\times 10^{-3}\\ \\mathrm{mm}^2/\\mathrm{s}$ is incompatible with a hemorrhagic cyst.\n        - The absence of T$2$ \"shading\" argues against an endometrioma or a chronic hemorrhagic process, where iron deposition (hemosiderin) would cause a drop in T$2$ signal.\n\n**Conclusion:** The overwhelming evidence from the clinical presentation, laboratory results, and characteristic multi-modality imaging findings (especially gas on CT and profoundly restricted diffusion on MRI) definitively identifies the lesion as a Tubo-Ovarian Abscess.\n\n### Option-by-Option Analysis\n\n**A. Tubo-ovarian abscess requiring broad-spectrum intravenous antibiotics, with image-guided drainage if there is lack of clinical improvement**\nThis option correctly identifies the lesion as a tubo-ovarian abscess based on the synthesis of all provided data. The proposed management is the standard of care for a hemodynamically stable patient with a large TOA and systemic signs of infection. Initial management involves hospitalization for intravenous broad-spectrum antibiotics. For a large abscess (this one is nearly $7\\ \\mathrm{cm}$) or in cases of non-response to antibiotics within $48-72$ hours, image-guided drainage is the indicated next step to achieve source control. This option is entirely consistent with the derived diagnosis and established clinical guidelines.\n**Verdict: Correct**\n\n**B. Hemorrhagic ovarian cyst managed conservatively with analgesia and repeat imaging in $6$–$8$ weeks**\nThis diagnosis is definitively contradicted by the clinical signs of severe infection (fever, purulent discharge), the laboratory evidence of a robust inflammatory response, and particularly by the pathognomonic imaging findings of gas within the lesion (CT) and a very low ADC value (MRI). Managing a TOA with only analgesia would be a critical medical error leading to progression of sepsis and potential rupture.\n**Verdict: Incorrect**\n\n**C. Ovarian torsion requiring urgent laparoscopic detorsion**\nThis diagnosis is inconsistent with the findings. The clinical picture of high fever and purulent discharge is not typical for torsion. Most importantly, the Doppler ultrasound finding of *peripheral hyperemia* (increased flow) is the opposite of the expected finding in torsion, which is absent or decreased stromal blood flow.\n**Verdict: Incorrect**\n\n**D. Ruptured ectopic pregnancy requiring emergent surgical management**\nThis diagnosis is definitively ruled out by the negative urine hCG test. An ectopic pregnancy cannot exist in the absence of hCG production.\n**Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "4484828"}, {"introduction": "Effective treatment of a TOA hinges on achieving adequate antibiotic concentrations at the site of infection. This advanced practice moves beyond standard dosing guidelines to explore the underlying pharmacokinetic and pharmacodynamic (PK/PD) principles that dictate therapeutic success. By modeling drug concentrations over time, you will calculate the optimal dosing frequency for common beta-lactam antibiotics to achieve a specific efficacy target ($fT_{>\\text{MIC}}$), providing a quantitative foundation for rational antibiotic therapy [@problem_id:4484890].", "problem": "A nonpregnant adult with pelvic inflammatory disease (PID) is being treated with beta-lactam antibiotics. Assume a one-compartment model with first-order elimination, linear pharmacokinetics, and rapid intravenous administration such that each dose can be approximated as an instantaneous bolus relative to the elimination half-life. Let the total plasma concentration after a bolus dose be governed by exponential decay and assume steady state under repeated dosing.\n\nUse the well-tested pharmacodynamic principle that, for beta-lactams such as cephalosporins, clinical efficacy correlates with the fraction of each dosing interval during which the unbound (free) plasma concentration exceeds the minimum inhibitory concentration (MIC), and that a reasonable target for clinical success in moderate infections is unbound fraction time above MIC (fraction of time greater than the minimum inhibitory concentration, $fT_{>\\text{MIC}}$) of at least $0.5$ per dosing interval.\n\nConsider two agents commonly used in PID regimens:\n\n- Cefoxitin: dose $D = 2000$ mg, elimination half-life $t_{1/2} = 0.8$ h, unbound fraction $f_u = 0.30$, volume of distribution $V_d = 0.20$ L/kg in a $70$ kg patient.\n- Ceftriaxone: dose $D = 1000$ mg, elimination half-life $t_{1/2} = 8.0$ h, unbound fraction $f_u = 0.10$, volume of distribution $V_d = 0.12$ L/kg in a $70$ kg patient.\n\nAssume the same minimum inhibitory concentration for the target organisms of $MIC = 1$ mg/L for both agents. Let repeated doses be given at a fixed interval of $\\tau$ hours, achieving steady state. Define the number of doses per $24$ hours as $n = 24 / \\tau$. Using only core pharmacokinetic definitions for first-order elimination and superposition at steady state, derive the condition on $\\tau$ such that $fT_{>\\text{MIC}} \\ge 0.5$ in each dosing interval for each drug, and from this compute the minimum integer $n$ that satisfies the target for each agent.\n\nExpress your final answer as a row matrix $\\begin{pmatrix} n_{\\text{cefoxitin}}  n_{\\text{ceftriaxone}} \\end{pmatrix}$ with no units. No rounding by significant figures is required because $n$ must be reported as the minimal whole number of doses per $24$ hours that achieves the target.", "solution": "The problem is evaluated as scientifically grounded, well-posed, and objective. It is based on standard pharmacokinetic and pharmacodynamic principles (one-compartment model, first-order elimination, steady state, and the $fT_{>\\text{MIC}}$ target for beta-lactams). All data required for a unique solution are provided, and the terms are defined precisely. Therefore, the problem is valid and a solution will be provided.\n\nLet $C_{\\text{ss}}(t)$ be the total plasma concentration at time $t$ within a dosing interval $[0, \\tau]$ at steady state. For an intravenous bolus dose $D$ in a one-compartment model with volume of distribution $V_d$ and first-order elimination rate constant $k_e$, the concentration profile is given by:\n$$C_{\\text{ss}}(t) = C_{\\text{max,ss}} \\exp(-k_e t)$$\nwhere $t$ is the time elapsed since the last dose. The peak steady-state concentration, $C_{\\text{max,ss}}$, is given by the superposition principle:\n$$C_{\\text{max,ss}} = \\frac{D/V_d}{1 - \\exp(-k_e \\tau)}$$\nThe elimination rate constant $k_e$ is related to the elimination half-life $t_{1/2}$ by:\n$$k_e = \\frac{\\ln(2)}{t_{1/2}}$$\nThe unbound (free) plasma concentration, $C_{u, \\text{ss}}(t)$, is the product of the total concentration and the unbound fraction, $f_u$:\n$$C_{u, \\text{ss}}(t) = f_u C_{\\text{ss}}(t) = f_u C_{\\text{max,ss}} \\exp(-k_e t)$$\nThe pharmacodynamic target is that the fraction of the dosing interval during which the unbound concentration exceeds the minimum inhibitory concentration ($MIC$) is at least $0.5$. Let this duration be $T_{>MIC}$. The condition is:\n$$\\frac{T_{>MIC}}{\\tau} \\ge 0.5$$\nSince $C_{u, \\text{ss}}(t)$ is a monotonically decreasing function of time $t$ in the interval $[0, \\tau]$, the condition that the drug concentration is above the $MIC$ for at least half the dosing interval is equivalent to the condition that the concentration at the midpoint of the interval, $t = \\tau/2$, is greater than or equal to the $MIC$:\n$$C_{u, \\text{ss}}(t=\\tau/2) \\ge MIC$$\nSubstituting the expressions for concentration, we obtain the governing inequality for $\\tau$:\n$$f_u \\left( C_{\\text{max,ss}} \\exp\\left(-k_e \\frac{\\tau}{2}\\right) \\right) \\ge MIC$$\n$$f_u \\left( \\frac{D/V_d}{1 - \\exp(-k_e \\tau)} \\right) \\exp\\left(-\\frac{k_e \\tau}{2}\\right) \\ge MIC$$\nTo simplify, let $x = \\exp\\left(-\\frac{k_e \\tau}{2}\\right)$. Then $\\exp(-k_e \\tau) = x^2$. The inequality becomes:\n$$\\frac{f_u (D/V_d)}{1 - x^2} x \\ge MIC$$\nSince $0  \\tau  \\infty$, we have $0  x  1$, which means $1 - x^2  0$. We can rearrange to solve for $x$:\n$$f_u \\frac{D}{V_d} x \\ge MIC (1 - x^2)$$\n$$MIC \\cdot x^2 + f_u \\frac{D}{V_d} x - MIC \\ge 0$$\nDividing by $MIC$ (which is non-zero) yields a quadratic inequality in $x$:\n$$x^2 + \\left(\\frac{f_u D}{V_d \\cdot MIC}\\right) x - 1 \\ge 0$$\nThis inequality holds for $x \\ge x_0$, where $x_0$ is the positive root of the corresponding quadratic equation $x^2 + \\left(\\frac{f_u D}{V_d \\cdot MIC}\\right) x - 1 = 0$.\nUsing the quadratic formula, the positive root is:\n$$x_0 = \\frac{-\\left(\\frac{f_u D}{V_d \\cdot MIC}\\right) + \\sqrt{\\left(\\frac{f_u D}{V_d \\cdot MIC}\\right)^2 - 4(1)(-1)}}{2}$$\nThe condition $x \\ge x_0$ translates back to an inequality for $\\tau$:\n$$\\exp\\left(-\\frac{k_e \\tau}{2}\\right) \\ge x_0$$\n$$-\\frac{k_e \\tau}{2} \\ge \\ln(x_0)$$\n$$\\tau \\le \\frac{-2\\ln(x_0)}{k_e} = \\frac{-2\\ln(x_0) t_{1/2}}{\\ln(2)}$$\nThis defines the maximum allowable dosing interval, $\\tau_{\\text{max}}$, for each agent. The number of doses per $24$ hours is $n = 24/\\tau$. The condition $\\tau \\le \\tau_{\\text{max}}$ implies $n \\ge \\frac{24}{\\tau_{\\text{max}}}$. We must find the minimum integer $n$ that satisfies this.\n\n**Cefoxitin Analysis**\nGiven parameters:\n$D = 2000$ mg\n$t_{1/2} = 0.8$ h\n$f_u = 0.30$\n$V_d = 0.20$ L/kg for a patient of weight $W = 70$ kg, so total $V_d = 0.20 \\times 70 = 14$ L.\n$MIC = 1$ mg/L\nFirst, compute the coefficient for the quadratic:\n$$\\frac{f_u D}{V_d \\cdot MIC} = \\frac{0.30 \\times 2000 \\text{ mg}}{(14 \\text{ L}) \\times (1 \\text{ mg/L})} = \\frac{600}{14} = \\frac{300}{7} \\approx 42.857$$\nThe quadratic equation for $x$ is $x^2 + \\frac{300}{7}x - 1 = 0$. The positive root $x_0$ is:\n$$x_0 = \\frac{-\\frac{300}{7} + \\sqrt{\\left(\\frac{300}{7}\\right)^2 + 4}}{2} = \\frac{-300 + \\sqrt{300^2 + 4 \\cdot 49}}{14} = \\frac{-300 + \\sqrt{90196}}{14} \\approx 0.02332$$\nNow we find the maximum dosing interval $\\tau_{\\text{max, cefoxitin}}$:\n$$\\tau_{\\text{max, cefoxitin}} = \\frac{-2\\ln(x_0) t_{1/2}}{\\ln(2)} \\approx \\frac{-2\\ln(0.02332) \\times 0.8}{\\ln(2)} \\approx \\frac{-2(-3.7586) \\times 0.8}{0.6931} \\approx \\frac{6.0138}{0.6931} \\approx 8.676 \\text{ h}$$\nThe minimum number of doses per $24$ hours is:\n$$n_{\\text{cefoxitin}} \\ge \\frac{24}{\\tau_{\\text{max, cefoxitin}}} \\approx \\frac{24}{8.676} \\approx 2.766$$\nSince $n$ must be an integer, the minimum number of doses is $n_{\\text{cefoxitin}} = 3$.\n\n**Ceftriaxone Analysis**\nGiven parameters:\n$D = 1000$ mg\n$t_{1/2} = 8.0$ h\n$f_u = 0.10$\n$V_d = 0.12$ L/kg for a patient of weight $W = 70$ kg, so total $V_d = 0.12 \\times 70 = 8.4$ L.\n$MIC = 1$ mg/L\nFirst, compute the coefficient for the quadratic:\n$$\\frac{f_u D}{V_d \\cdot MIC} = \\frac{0.10 \\times 1000 \\text{ mg}}{(8.4 \\text{ L}) \\times (1 \\text{ mg/L})} = \\frac{100}{8.4} = \\frac{1000}{84} = \\frac{250}{21} \\approx 11.905$$\nThe quadratic equation for $x$ is $x^2 + \\frac{250}{21}x - 1 = 0$. The positive root $x_0$ is:\n$$x_0 = \\frac{-\\frac{250}{21} + \\sqrt{\\left(\\frac{250}{21}\\right)^2 + 4}}{2} = \\frac{-250 + \\sqrt{250^2 + 4 \\cdot 21^2}}{42} = \\frac{-250 + \\sqrt{64264}}{42} \\approx 0.08339$$\nNote that this is very close to $1/12 \\approx 0.08333$.\nNow we find the maximum dosing interval $\\tau_{\\text{max, ceftriaxone}}$:\n$$\\tau_{\\text{max, ceftriaxone}} = \\frac{-2\\ln(x_0) t_{1/2}}{\\ln(2)} \\approx \\frac{-2\\ln(0.08339) \\times 8.0}{\\ln(2)} \\approx \\frac{-2(-2.4842) \\times 8.0}{0.6931} \\approx \\frac{39.747}{0.6931} \\approx 57.34 \\text{ h}$$\nThe minimum number of doses per $24$ hours is:\n$$n_{\\text{ceftriaxone}} \\ge \\frac{24}{\\tau_{\\text{max, ceftriaxone}}} \\approx \\frac{24}{57.34} \\approx 0.4185$$\nSince $n$ must be an integer, the minimum number of doses is $n_{\\text{ceftriaxone}} = 1$.\n\nThe minimum integer number of doses per $24$ hours required to meet the target $fT_{>\\text{MIC}} \\ge 0.5$ is $3$ for cefoxitin and $1$ for ceftriaxone.", "answer": "$$\\boxed{\\begin{pmatrix} 3  1 \\end{pmatrix}}$$", "id": "4484890"}]}